571188-59-5CC(C)(C)OC(=O)N1CCN(c2ccc(N)nc2)CC1RMULRXHUNOVPEI-UHFFFAOYSA-NSicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H301 (11.1%): Toxic if swallowed [Danger Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P272, P280, P301+P316, P301+P317, P302+P352, P304+P340, P305+P351+P338, P305+P354+P338, P317, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 9 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
BeschreibungTert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate is a pharmaceutical intermediate compound that can be used to synthesize the targeted cancer drug Ribociclib for the treatment of ER-positive and HER2-negative breast cancer.
Verwenden4-(6-Amino-3-pyridyl)-1-Boc-piperazine (tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate) is used as an organic chemical synthesis intermediate.
synthetische4- (6-Nitro-pyridin-3-yl)-piperazine-1 -carboxylic acid ie f-butyl ester and Pd/C in ethanol is stirred with an H2 balloon for 3 h. The product tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate is obtained through purification.
571188-59-5DTXSID10471464CHEMBL4534399